{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:15:21Z","timestamp":1770513321385,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00115-016-0163-4","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T10:03:32Z","timestamp":1467885812000},"page":"1086-1093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brivaracetam zur Zusatztherapie bei fokalen Epilepsien","Brivaracetam for add-on treatment in focal epilepsy"],"prefix":"10.1007","volume":"87","author":[{"given":"A.","family":"Strzelczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Steinig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Knake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"issue":"6","key":"163_CR1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00019053-200826060-00002","volume":"26","author":"A Strzelczyk","year":"2008","unstructured":"Strzelczyk A, Reese JP, Dodel R, Hamer HM (2008) Cost of epilepsy: a systematic review. Pharmacoeconomics 26(6):463\u2013476","journal-title":"Pharmacoeconomics"},{"key":"163_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12883-015-0494-y","volume":"15","author":"K Allers","year":"2015","unstructured":"Allers K, Essue BM, Hackett ML, Muhunthan J, Anderson CS, Pickles K, Scheibe F, Jan S (2015) The economic impact of epilepsy: a systematic review. BMC Neurol 15:245","journal-title":"BMC Neurol"},{"issue":"5","key":"163_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J\u00a0Med 342(5):314\u2013319","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"163_CR4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"365","author":"P Kwan","year":"2011","unstructured":"Kwan P, Schachter SC, Brodie MJ (2011) Drug-resistant epilepsy. N Engl J\u00a0Med 365(10):919\u2013926","journal-title":"N. Engl. J. Med."},{"issue":"6S2","key":"163_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1525-5050(02)00545-0","volume":"3","author":"A Jacoby","year":"2002","unstructured":"Jacoby A (2002) Stigma, epilepsy, and quality of life. Epilepsy Behav 3(6S2):10\u201320","journal-title":"Epilepsy Behav"},{"issue":"9","key":"163_CR6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/epi.13089","volume":"56","author":"J Riechmann","year":"2015","unstructured":"Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C, Neubauer BA, Oberman B, Philippi H, Rochel M et al (2015) Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia 56(9):1388\u20131397","journal-title":"Epilepsia"},{"issue":"3","key":"163_CR7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2007.02.006","volume":"10","author":"VM Smeets","year":"2007","unstructured":"Smeets VM, Lierop BA van, Vanhoutvin JP, Aldenkamp AP, Nijhuis FJ (2007) Epilepsy and employment: literature review. Epilepsy Behav 10(3):354\u2013362","journal-title":"Epilepsy Behav"},{"issue":"11","key":"163_CR8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1474-4422(11)70193-4","volume":"10","author":"P Ryvlin","year":"2011","unstructured":"Ryvlin P, Cucherat M, Rheims S (2011) Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 10(11):961\u2013968","journal-title":"Lancet Neurol"},{"issue":"3","key":"163_CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.yebeh.2013.03.007","volume":"27","author":"A Strzelczyk","year":"2013","unstructured":"Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, Knake S, Rosenow F, Hamer HM (2013) Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav 27(3):433\u2013438","journal-title":"Epilepsy Behav"},{"issue":"4","key":"163_CR10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","volume":"62","author":"AL Luciano","year":"2007","unstructured":"Luciano AL, Shorvon SD (2007) Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 62(4):375\u2013381","journal-title":"Ann. Neurol."},{"issue":"3","key":"163_CR11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1528-1167.2010.02929.x","volume":"52","author":"B Callaghan","year":"2011","unstructured":"Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W, French J (2011) Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia 52(3):619\u2013626","journal-title":"Epilepsia"},{"issue":"8","key":"163_CR12","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"A Matagne","year":"2008","unstructured":"Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H (2008) Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J\u00a0Pharmacol 154(8):1662\u20131671","journal-title":"Br. J. Pharmacol."},{"issue":"1\u20133","key":"163_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J\u00a0Pharmacol 664(1\u20133):36\u201344","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20133","key":"163_CR14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2008.10.048","volume":"601","author":"M Hamann","year":"2008","unstructured":"Hamann M, Sander SE, Richter A (2008) Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. Eur J\u00a0Pharmacol 601(1\u20133):99\u2013102","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"163_CR15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cmdc.201200183","volume":"7","author":"S Hildenbrand","year":"2012","unstructured":"Hildenbrand S, Schoch S, Lehe M von, Surges R, Muller CE (2012) Tritium-labeled brivaracetam with high specific activity: preparation, characterization and application in human brain samples. ChemMedChem 7(8):1369\u20131374","journal-title":"ChemMedChem"},{"issue":"3","key":"163_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/13543784.17.3.361","volume":"17","author":"B Malawska","year":"2008","unstructured":"Malawska B, Kulig K (2008) Brivaracetam: a new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs 17(3):361\u2013369","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"163_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/cns.12347","volume":"21","author":"I Niespodziany","year":"2015","unstructured":"Niespodziany I, Andre VM, Leclere N, Hanon E, Ghisdal P, Wolff C (2015) Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther 21(3):241\u2013251","journal-title":"CNS Neurosci Ther"},{"issue":"8","key":"163_CR18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/bjp.2008.221","volume":"154","author":"MA Rogawski","year":"2008","unstructured":"Rogawski MA (2008) Brivaracetam: a rational drug discovery success story. Br J\u00a0Pharmacol 154(8):1555\u20131557","journal-title":"Br. J. Pharmacol."},{"issue":"26","key":"163_CR19","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101(26):9861\u20139866","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"163_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.nurt.2006.11.004","volume":"4","author":"P Rosenstiel von","year":"2007","unstructured":"Rosenstiel P von (2007) Brivaracetam (UCB 34714). Neurotherapeutics 4(1):84\u201387","journal-title":"Neurotherapeutics"},{"key":"163_CR21","volume-title":"Briviact \u2013 Anhang I \u2013 Zusammenfassung der Merkmale des Arzneimittels","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency (2016) Briviact \u2013 Anhang I \u2013 Zusammenfassung der Merkmale des Arzneimittels. European Medicines Agency, London"},{"issue":"Pt A","key":"163_CR22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Liang W, Eckhardt K, Borghs S, D\u2019Souza J (2015) An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav 52(Pt A):165\u2013168","journal-title":"Epilepsy Behav"},{"issue":"1","key":"163_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J\u00a0Clin Pharmacol 66(1):71\u201375","journal-title":"Br J\u00a0Clin Pharmacol"},{"issue":"1","key":"163_CR24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/dmd.107.017129","volume":"36","author":"ML Sargentini-Maier","year":"2008","unstructured":"Sargentini-Maier ML, Espie P, Coquette A, Stockis A (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36(1):36\u201345","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"163_CR25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2125.2006.02829.x","volume":"63","author":"ML Sargentini-Maier","year":"2007","unstructured":"Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, Stockis A (2007) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J\u00a0Clin Pharmacol 63(6):680\u2013688","journal-title":"Br J\u00a0Clin Pharmacol"},{"issue":"12","key":"163_CR26","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/0091270011431457","volume":"52","author":"ML Sargentini-Maier","year":"2012","unstructured":"Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T, Stockis A (2012) Brivaracetam disposition in renal impairment. J\u00a0Clin Pharmacol 52(12):1927\u20131933","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"163_CR27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/jcph.82","volume":"53","author":"A Stockis","year":"2013","unstructured":"Stockis A, Sargentini-Maier ML, Horsmans Y (2013) Brivaracetam disposition in mild to severe hepatic impairment. J\u00a0Clin Pharmacol 53(6):633\u2013641","journal-title":"J Clin Pharmacol"},{"issue":"2\u20133","key":"163_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","volume":"92","author":"M Bialer","year":"2010","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2010) Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 92(2\u20133):89\u2013124","journal-title":"Epilepsy Res."},{"key":"163_CR29","first-page":"5719","volume":"9","author":"L Mumoli","year":"2015","unstructured":"Mumoli L, Palleria C, Gasparini S, Citraro R, Labate A, Ferlazzo E, Gambardella A, De Sarro G, Russo E (2015) Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther 9:5719\u20135725","journal-title":"Drug Des Devel Ther"},{"key":"163_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2015.03.003","volume":"113","author":"A Stockis","year":"2015","unstructured":"Stockis A, Chanteux H, Rosa M, Rolan P (2015) Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res 113:19\u201327","journal-title":"Epilepsy Res."},{"issue":"5","key":"163_CR31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jcph.446","volume":"55","author":"A Stockis","year":"2015","unstructured":"Stockis A, Watanabe S, Scheen AJ (2015) Effect of brivaracetam on CYP3A activity, measured by oral midazolam. J\u00a0Clin Pharmacol 55(5):543\u2013548","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"163_CR32","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/epi.12535","volume":"55","author":"A Stockis","year":"2014","unstructured":"Stockis A, Watanabe S, Fauchoux N (2014) Interaction between brivaracetam (100\u202fmg\/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia 55(3):e27\u201331","journal-title":"Epilepsia"},{"issue":"10","key":"163_CR33","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1212\/01.wnl.0000271385.85302.55","volume":"69","author":"DG Kasteleijn-Nolst Trenite","year":"2007","unstructured":"Kasteleijn-Nolst Trenite DG, Genton P, Parain D, Masnou P, Steinhoff BJ, Jacobs T, Pigeolet E, Stockis A, Hirsch E (2007) Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 69(10):1027\u20131034","journal-title":"Neurology"},{"issue":"1","key":"163_CR34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1528-1167.2012.03598.x","volume":"54","author":"W Paesschen Van","year":"2013","unstructured":"Van Paesschen W, Hirsch E, Johnson M, Falter U, Rosenstiel P von (2013) Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 54(1):89\u201397","journal-title":"Epilepsia"},{"issue":"1","key":"163_CR35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/epi.12433","volume":"55","author":"V Biton","year":"2014","unstructured":"Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S (2014) Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 55(1):57\u201366","journal-title":"Epilepsia"},{"issue":"12","key":"163_CR36","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/epi.13212","volume":"56","author":"P Klein","year":"2015","unstructured":"Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T, Brandt C, Kwan P (2015) A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 56(12):1890\u20131898","journal-title":"Epilepsia"},{"issue":"1","key":"163_CR37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/epi.12391","volume":"55","author":"P Kwan","year":"2014","unstructured":"Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S (2014) Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 55(1):38\u201346","journal-title":"Epilepsia"},{"issue":"1","key":"163_CR38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/epi.12432","volume":"55","author":"P Ryvlin","year":"2014","unstructured":"Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S (2014) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 55(1):47\u201356","journal-title":"Epilepsia"},{"key":"163_CR39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eplepsyres.2015.04.017","volume":"114","author":"J Ma","year":"2015","unstructured":"Ma J, Huang S, You C (2015) Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials. Epilepsy Res 114:59\u201365","journal-title":"Epilepsy Res."},{"issue":"12","key":"163_CR40","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1517\/14656566.2015.1058360","volume":"16","author":"X Tian","year":"2015","unstructured":"Tian X, Yuan M, Zhou Q, Wang X (2015) The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies. Expert Opin Pharmacother 16(12):1755\u20131767","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"163_CR41","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","volume":"86","author":"S Lattanzi","year":"2016","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M (2016) Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis. Neurology 86(14):1344\u20131352","journal-title":"Neurology"},{"issue":"6","key":"163_CR42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/WNL.0b013e3181ec7f7f","volume":"75","author":"JA French","year":"2010","unstructured":"French JA, Costantini C, Brodsky A, Rosenstiel P von, Group NS (2010) Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 75(6):519\u2013525","journal-title":"Neurology"},{"issue":"8","key":"163_CR43","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1185\/03007990802278453","volume":"24","author":"D Rosillon","year":"2008","unstructured":"Rosillon D, Astruc B, Hulhoven R, Meeus MA, Troenaru MM, Watanabe S, Stockis A (2008) Effect of brivaracetam on cardiac repolarisation \u2013 a thorough QT study. Curr Med Res Opin 24(8):2327\u20132337","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"163_CR44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1528-1167.2010.02746.x","volume":"52","author":"KJ Meador","year":"2011","unstructured":"Meador KJ, Gevins A, Leese PT, Otoul C, Loring DW (2011) Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia 52(2):264\u2013272","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"163_CR45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1528-1157.2001.0420s4024.x","volume":"42","author":"RA Radtke","year":"2001","unstructured":"Radtke RA (2001) Pharmacokinetics of levetiracetam. Epilepsia 42(Suppl 4):24\u201327","journal-title":"Epilepsia"},{"issue":"5","key":"163_CR46","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-2125.2006.02782.x","volume":"63","author":"Q Zhao","year":"2007","unstructured":"Zhao Q, Jiang J, Li X, Lu ZS, Hu P (2007) Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J\u00a0Clin Pharmacol 63(5):614\u2013617","journal-title":"Br J\u00a0Clin Pharmacol"},{"issue":"1","key":"163_CR47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.eplepsyres.2009.09.024","volume":"88","author":"C Zona","year":"2010","unstructured":"Zona C, Pieri M, Carunchio I, Curcio L, Klitgaard H, Margineanu DG (2010) Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 88(1):46\u201354","journal-title":"Epilepsy Res."},{"issue":"12","key":"163_CR48","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/epi.13223","volume":"56","author":"X Yang","year":"2015","unstructured":"Yang X, Bognar J Jr., He T, Mohammed M, Niespodziany I, Wolff C, Esguerra M, Rothman SM, Dubinsky JM (2015) Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia 56(12):1899\u20131909","journal-title":"Epilepsia"},{"issue":"2","key":"163_CR49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","volume":"57","author":"JM Nicolas","year":"2016","unstructured":"Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A et al (2016) Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 57(2):201\u2013209","journal-title":"Epilepsia"},{"issue":"5","key":"163_CR50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/17512433.2016.1156529","volume":"9","author":"A Strzelczyk","year":"2016","unstructured":"Strzelczyk A, Klein KM, Willems LM, Rosenow F, Bauer S (2016) Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 9(5):637\u2013645","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"163_CR51","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00115-016-0087-z","volume":"87","author":"A Strzelczyk","year":"2016","unstructured":"Strzelczyk A, Hamer HM (2016) Auswirkungen der fr\u00fchen Nutzenbewertung auf Patienten mit Epilepsie in Deutschland : Aktuelle Versorgungsrealitat und therapeutischer Bedarf. Nervenarzt 87(4):386\u2013393","journal-title":"Nervenarzt"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-016-0163-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T04:12:06Z","timestamp":1718683926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-016-0163-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["163"],"URL":"https:\/\/doi.org\/10.1007\/s00115-016-0163-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]}}}